Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment

This article synthesizes the evidence on the cost-effectiveness of renal replacement therapy and discusses the findings in light of the frequent practice of using the cost-effectiveness of hemodialysis as a benchmark of societal willingness to pay. The authors conducted a meta-analytic review of the medical and economic literature for economic evaluations of hemodialysis, peritoneal dialysis, and kidney transplantation. Cost-effectiveness ratios were translated into 2000 U.S. dollars per life-year (LY) saved. Thirteen studies published between 1968 and 1998 provided such information. The cost-effectiveness of center hemodialysis remained within a narrow range of $55,000 to $80,000/LY in most studies despite considerable variation in methodology and imputed costs. The cost-effectiveness of home hemodialysis was found to be between $33,000 and $50,000/LY. Kidney transplantation, however, has become more cost-effective over time, approaching $10,000/LY. Estimates of the cost per life-year gained from hemodialysis have been remarkably stable over the past 3 decades, after adjusting for price levels. Uses of the cost-effectiveness ratio of $55,000/LY for center hemodialysis as a lower boundary of society’s willingness to pay for an additional life-year can be supported under certain assumptions.

[1]  J. Eisenberg,et al.  Cost-Effectiveness Analysis of the Treatment of End-Stage Renal Disease in Brazil , 1990, International Journal of Technology Assessment in Health Care.

[2]  A. Laupacis,et al.  A study of the quality of life and cost-utility of renal transplantation. , 1996, Kidney international.

[3]  A. Nissenson,et al.  ESRD modality selection into the 21st century: the importance of non medical factors. , 1997, ASAIO journal.

[4]  Tammy O. Tengs,et al.  One thousand health-related quality-of-life estimates. , 2000, Medical care.

[5]  D. Eddy Screening for cervical cancer. , 1990, Annals of internal medicine.

[6]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[7]  M. Drummond,et al.  Cost-effectiveness league tables: more harm than good? , 1993, Social science & medicine.

[8]  Anne Ludbrook,et al.  A cost-effectiveness analysis of the treatment of chronic renal failure , 1981 .

[9]  J. Nixon,et al.  Summarising economic evaluations in systematic reviews: a new approach , 2001, BMJ : British Medical Journal.

[10]  G. Torrance,et al.  A Cost-Effectiveness Analysis of Continuous Ambulatory Peritoneal Dialysis and Hospital Hemodialysis , 1984 .

[11]  G A de Wit,et al.  Economic evaluation of end stage renal disease treatment. , 1998, Health policy.

[12]  T. Garner,et al.  Cost-effectiveness Analysis of End-stage Renal Disease Treatments , 1987, Medical care.

[13]  D. Huse,et al.  Cost-effectiveness of statins. , 1998, The American journal of cardiology.

[14]  J. H. Harrison,et al.  Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. , 1963, Annals of plastic surgery.

[15]  H. Klarman,et al.  Cost Effectiveness Analysis Applied to the Treatment of Chronic Renal Disease , 1968 .

[16]  P. Cleary,et al.  The effect of patients' preferences on racial differences in access to renal transplantation. , 1999, The New England journal of medicine.

[17]  J. H. Harrison,et al.  Successful homotransplantation of the human kidney between identical twins. , 1956, Journal of the American Medical Association.

[18]  S. D. Roberts,et al.  Cost-effective care of end-stage renal disease: a billion dollar question. , 1980, Annals of internal medicine.

[19]  G. Nyberg,et al.  Cost-Effectiveness Studies of Renal Transplantation , 1995, International Journal of Technology Assessment in Health Care.

[20]  M. Buxton,et al.  Cost-benefit analysis of long-term haemodialysis for chronic renal failure. , 1975, British medical journal.

[21]  E. Jonsson,et al.  Cost-Effectiveness Analysis of Organ Transplantation , 1986, International Journal of Technology Assessment in Health Care.

[22]  B. Croxson,et al.  A cost effectiveness analysis of the treatment of end stage renal failure. , 1990, The New Zealand medical journal.

[23]  B. Scribner,et al.  Cannulation of blood vessels for prolonged hemodialysis * , 2004, Hemodialysis international. International Symposium on Home Hemodialysis.

[24]  G. Torrance,et al.  The utility of different health states as perceived by the general public. , 1978, Journal of chronic diseases.

[25]  U. Gelatti,et al.  Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  M. Mcgrath Cost Effectiveness in Health and Medicine. , 1998 .

[27]  J. Moncrief Continuous ambulatory peritoneal dialysis. , 1986, Artificial organs.

[28]  A. T. Sumner,et al.  Predicting treatment costs and life expectancy for end-stage renal disease. , 1978, The New England journal of medicine.

[29]  J. Avorn,et al.  Late referral and modality choice in end-stage renal disease. , 2001, Kidney international.